Germany’s cannabidiol scene has shifted markedly over recent years, anchored in its long heritage of medicinal cannabis use under Germany’s Narcotics Act and evolving through robust pharmaceutical‑standards regulation. Firms such as Maricann started offering softgel preparations with standardized cannabidiol formulations in 2018, introducing their MariPlant line with measured concentrations sold through pharmacies in Munich and Cologne. The German Federal Institute for Risk Assessment (BfR) has flagged cannabidiol extracts as “novel foods,” meaning that edibles, oils, and supplements containing extracts must undergo authorisation under EU Regulation 2015/2283 before being legally marketed as consumables. Full‑spectrum extracts containing terpenes and minor cannabinoids are under particular scrutiny in Germany versus isolates that contain purified cannabidiol with minimal other plant compounds. Companies such as Clever Leaves, in partnership with Ethypharm, have supplied cannabidiol extracts in pharmaceutical‑grade form to German pharmacies under strict EU‑GMP standards. CC Pharma, a subsidiary of Aphria, has introduced cosmetic lines like CannRelief in Germany with topical oils and creams at 5 % and 10 % concentrations, paying special attention to packaging regulations, child‑resistant closures, and potency labelling.

Safety agencies have even documented possible adverse effects including sedation, liver enzyme elevations and interactions with other medications when high doses are used, per publications by BfR. Administrative courts in cities like Cologne have issued rulings classifying many oral cannabidiol drops marketed as supplements into medicinal classification because of their pharmacological effect. Meanwhile, transparency mechanisms have grown in importance, with third‑party labs used for verifying residual THC levels, pesticide residues and general purity being a requirement for firms seeking certification or inclusion in pharmacy‑based product portfolios. These developments show that Germany has moved from a phase of uncertain regulatory status toward one of tightened legal compliance, elevated product safety and more structured marketplace expectations.According to the research report, "Germany Cannabidiol Market Research Report, 2030," published by Actual Market Research, the Germany Cannabidiol market is anticipated to grow at more than 15.10% CAGR from 2025 to 2030. In Germany there are prominent names that have shaped cannabidiol commerce through both medical and wellness sectors including Neuraxpharm which partnered with Israel’s Panaxia Labs to launch prescription medical cannabis products, and Maricann bringing VESIsorb® softgels into pharmacies as part of its MariPlant range. Online platforms are active too, Blessed CBD (subsidiary of High Tide Inc.) sells full‑spectrum products such as oils, gummies and creams via its German website using fulfillment through the EU, targeting consumers seeking topical and edible options. Physical retail remains heavily regulated medical grade extracts and prescription products must be dispensed by certified pharmacies while cosmetic products are sold through drugstores and specialty wellness shops under compliance with cosmetic regulation.

Advertising for cannabidiol is subject to strict oversight Health Germany (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, BVL) and courts have prohibited unverified therapeutic claims, social media posts often emphasize general wellness, relief of stress or sleep rather than diagnosed medical conditions. Supply chains include imports from Colombia by Clever Leaves and laboratories across Europe carrying out EU‑GMP extraction, east German and North Rhine‑Westphalia facilities are noted for meeting high pesticide residue and THC‑contamination standards. Consumer preferences show growing interest in isolated cannabidiol or low‑THC broad extracts and irritation‑free topical formulations, transparency about sourcing from approved hemp cultivars in Lower Saxony or Brandenburg is increasingly valued. Novel product forms such as nanoemulsion tinctures have been introduced by small startups, yet many CBD edibles await approval via Novel Food authorization. Manufacturers face delays with regulatory approvals especially for food supplement status, and multiple court rulings (e.g. in Berlin and Hamburg) have confirmed that most ingestible cannabidiol‑extract foods remain unmarketable without official authorization. In Germany, marijuana-derived CBD is produced in compliance with the country's medical cannabis laws, which were liberalized in 2017 to allow for the prescription of cannabis products for medicinal use.

This has led to the rise of licensed cannabis producers and cultivators in regions such as North Rhine-Westphalia and Lower Saxony, where marijuana is grown specifically for medical and CBD use. These producers supply high-THC cannabis strains that are used to create both CBD and THC products, which are sold under strict medical regulations. Hemp-derived CBD dominates the German CBD market, with a large portion of CBD products being derived from hemp plants that are cultivated for their low-THC content. The German hemp market is growing, especially in rural regions such as Brandenburg and Bavaria, where hemp farming has become more prevalent due to favorable agricultural conditions and the country's positive stance toward industrial hemp. Hemp-derived CBD is used in a variety of products, from oils and tinctures to skincare products and supplements, and it makes up the majority of the consumer-facing CBD market in Germany. These hemp products are grown by licensed farmers who follow strict EU agricultural regulations and are processed in Germany's well-established hemp processing facilities, especially in areas like Mecklenburg-Vorpommern, where hemp production has seen significant expansion.

Due to Germany's strict regulations on marijuana cultivation, hemp-derived CBD products tend to be more widely available and accessible to the general public, and they are sold in both retail stores and online platforms across the country. Considered in this report• Historic Year: 2019• Base year: 2024• Estimated year: 2025• Forecast year: 2030Aspects covered in this report• Cannabidiol Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Form• Oils & Tinctures• Capsules & Softgels• Gummies & Confectionery• Topicals / Skin Care• Vape Products• OthersBy End Use• Wellness & Personal Use• Nutraceuticals & Supplements• Pet Care• Cosmetics & Skin Care• Pharmaceuticals• Food & BeveragesBy Source• Marijuana• Hemp.